Developer docs
API playgroundTry for free, no card

Search company profiles

VeraDermics

Full company profile

uuid0000dzo

Namestring
VeraDermics
Legal namestring
VeraDermics, Inc.
Websiteurl
veradermics.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil formulation designed to treat pattern hair loss (androgenetic alopecia) in men and women. The company's core technology targets the narrow gap between minoxidil's hair-growth efficacy threshold and its cardiac side-effect threshold by maintaining sustained plasma concentrations for 15-24 hours, versus 4-6 hours for immediate-release formulations, while avoiding the concentration spikes associated with cardiovascular adverse events. VeraDermics is currently running three Phase 3 registration-directed trials (Studies 302 and 304 in males and Study 306 in females), with composition-of-matter and formulation patent protection extending to 2043.

The company is pre-revenue and has no approved products, reporting a $70.0 million net loss for full year 2025 driven primarily by $62.1 million in R&D expense. Its future revenue model is expected to rely on prescription pharmaceutical sales of VDPHL01 upon FDA approval, with a planned go-to-market strategy combining specialty dermatology field sales with direct-to-consumer marketing aimed at the large cash-pay aesthetics consumer. VeraDermics is headquartered in New Haven, Connecticut, was incorporated in Delaware in 2019, and completed its IPO on the NYSE under ticker MANE in February 2026, followed by a $414.4 million follow-on offering in April 2026.

VeraDermics targets an addressable market of approximately 80 million Americans with androgenetic alopecia, and sell-side analyst modeling from Jefferies projects approximately $2 billion in peak US sales if VDPHL01 achieves expected penetration.

Short descriptiontext

VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermatology therapeutics, pattern hair loss, oral minoxidil, extended-release drug delivery, clinical-stage biopharmaceutical
Industry2 codes
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Dermatology Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue clinical stage
TypeHardware Sales
Description

Veradermics is a late clinical-stage biopharmaceutical company with no product revenue. The company reported a net loss of $53.81 million for the twelve months ending September 30, 2025, with zero product revenue. Future revenue model will be based on pharmaceutical product sales of VDPHL01 upon FDA approval, with Jefferies modeling approximately $2 billion in peak adjusted U.S. sales.

iposcoop.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Veradermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for pattern hair loss (androgenetic alopecia) in men and women. The sustained-release formulation maintains therapeutic plasma concentrations for 15-24 hours versus 4-6 hours for immediate-release oral minoxidil, with a release profile designed to avoid cardiac activity threshold spikes. VDPHL01 is currently in three Phase 3 registration-directed clinical trials (Studies 302 and 304 in males, Study 306 in females) and is being positioned as the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 30.3 hairs/cm² (once-daily) and 33.0-37.7 hairs/cm² (twice-daily) increase in target area hair count at Month 6 vs. 7.3 hairs/cm² for placebo (p<.0001)
+5 more records
Product overview1 text field

VeraDermics is a single-product-platform late clinical-stage biopharmaceutical company whose offerings are centered on VDPHL01, its lead investigational extended-release oral minoxidil candidate for pattern hair loss, evaluated through three Phase 3 trials (Study 302 in males, Study 304 in males, and Study 306 in females). VDPHL01 is the core asset around which all current clinical and commercial activity is organized, supported by a small portfolio of exploratory pipeline assets in alopecia areata, common warts, and molluscum contagiosum that may be advanced in the future. The company is dermatologist-founded and primarily delivers value through advancing VDPHL01 through FDA registration and commercialization rather than offering a multi-module SaaS-style platform.

Product and service4 records
1VDPHL01
CategoryLead product candidate (investigational drug)
Description

VDPHL01 is a proprietary, extended-release oral minoxidil tablet designed specifically for pattern hair loss in men and women. The extended-release formulation extends minoxidil plasma exposure to 15-24 hours versus 4-6 hours for immediate-release, while avoiding cardiac threshold spikes. Currently in three Phase 3 clinical trials (Studies 302 and 304 in males, Study 306 in females) with patent protection extending to 2043.

2Alopecia Areata Program
CategoryExploratory pipeline asset
Description

Exploratory pipeline asset in alopecia areata developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01, generated from the founders' real-world clinical experience as dermatologists.

3Common Warts Program
CategoryExploratory pipeline asset
Description

Exploratory pipeline asset in common warts treatment based on a dissolvable microneedle patch platform; part of Veradermics' broader dermatology portfolio originally developed as the company's lead program.

4Molluscum Contagiosum Program
CategoryExploratory pipeline asset
Description

Exploratory pipeline asset in molluscum contagiosum developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Veradermics CEO Reid Waldman, MD was appointed to Achieve Life Sciences' Board of Directors in June 2026, alongside Jeffrey Farrow. The appointment brings Veradermics' CEO expertise in aesthetics and dermatology therapeutics to Achieve's cytisinicline pipeline (smoking cessation NDA and vaping cessation Breakthrough Therapy-designated program).

Strategic tierMajorTypeStrategic or Co-development Partner
Description

John W. Childs, chairman of J.W. Childs Associates (private equity firm focusing on life sciences), serves on Veradermics' board of directors. J.W. Childs Associates is an early investor in the company. Mr. Childs also serves on boards of Biohaven Pharmaceuticals, Pyramid Biosciences, OMAX Health, Basin Holdings, and Realm LLC.

Strategic tierMajorTypeGTM or Marketing Partner
Description

Veradermics presented VDPHL01 data at the AAD Annual Meeting in Denver (March 2026), reaching the dermatology clinical community. Board member Jane Grant-Kels, MD previously served on the Board of Directors of the American Academy of Dermatology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Dermatology-focused biopharma with VTAMA (tapinarof) for psoriasis and atopic dermatitis, now part of Organon. Specialty dermatology pipeline and commercial model align directly with Veradermics' planned physician-channel and field-force GTM.

2Sun Pharmaceutical Industries
TypeDirect peer
Description

India-based global generic and specialty pharma that markets Loniten (immediate-release oral minoxidil), the off-label incumbent for pattern hair loss. Direct competitor to VDPHL01 given overlapping active ingredient and prescriber base.

TypeBroad incumbent
Description

Global dermatology specialty company spanning aesthetics, prescription dermatology, and consumer skincare. Comparable prescriber base and aesthetic dermatology channel that Veradermics will rely on for VDPHL01 commercialization.

TypeBroad incumbent
Description

Global biopharma that signaled a stake of up to 4.9% in Veradermics at IPO. Comparable as a potential strategic acquirer with significant aesthetics/dermatology franchise interest and financial capacity to acquire Veradermics outright post-NDA.

TypeBroad incumbent
Description

Global biopharma whose Allergan Aesthetics unit (Botox, CoolSculpting, Latisse) dominates aesthetic medicine. Comparable cash-pay aesthetics channel, dermatologist relationships, and potential acquirer profile for Veradermics.

6Revance Therapeutics
TypeDirect peer
Description

Aesthetic dermatology biopharma behind DAXXIFY and the former RHA filler line (sold to Crown Laboratories). Closely comparable aesthetics-focused specialty pharma model with dermatologist field sales force and similar cash-pay consumer dynamics to Veradermics' planned VDPHL01 launch.

TypeDirect peer
Description

Dermatology-focused biopharmaceutical company with approved topical treatments (ZORYVE) for plaque psoriasis and atopic dermatitis, plus pipeline in alopecia areata. Comparable late clinical-to-commercial dermatology specialty model with similar prescriber base and GTM motion.

TypeBroad incumbent
Description

Global biopharma that markets Rogaine (topical minoxidil), the incumbent OTC/prescription brand in pattern hair loss. Represents the established competitive incumbent VDPHL01 must displace, with massive DTC marketing scale.

TypeBroad incumbent
Description

Global women's health and dermatology specialty company with a portfolio including VTAMA and established dermatology sales infrastructure. Relevant given VDPHL01's female PHL opportunity and potential strategic acquirer profile for Veradermics.

TypeDirect peer
Description

Clinical-stage dermatology biopharma developing JAK inhibitors for alopecia areata and other inflammatory skin conditions. Most directly comparable to Veradermics in late-stage dermatology pipeline focus, public-company scale, and single-asset commercial economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VeraDermics

Dermatology Pharmaceuticalsveradermics.com

VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043.

What VeraDermics does

VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil formulation designed to treat pattern hair loss (androgenetic alopecia) in men and women. The company's core technology targets the narrow gap between minoxidil's hair-growth efficacy threshold and its cardiac side-effect threshold by maintaining sustained plasma concentrations for 15-24 hours, versus 4-6 hours for immediate-release formulations, while avoiding the concentration spikes associated with cardiovascular adverse events. VeraDermics is currently running three Phase 3 registration-directed trials (Studies 302 and 304 in males and Study 306 in females), with composition-of-matter and formulation patent protection extending to 2043.

The company is pre-revenue and has no approved products, reporting a $70.0 million net loss for full year 2025 driven primarily by $62.1 million in R&D expense. Its future revenue model is expected to rely on prescription pharmaceutical sales of VDPHL01 upon FDA approval, with a planned go-to-market strategy combining specialty dermatology field sales with direct-to-consumer marketing aimed at the large cash-pay aesthetics consumer. VeraDermics is headquartered in New Haven, Connecticut, was incorporated in Delaware in 2019, and completed its IPO on the NYSE under ticker MANE in February 2026, followed by a $414.4 million follow-on offering in April 2026.

VeraDermics targets an addressable market of approximately 80 million Americans with androgenetic alopecia, and sell-side analyst modeling from Jefferies projects approximately $2 billion in peak US sales if VDPHL01 achieves expected penetration.

VeraDermics firmographics

Firmographics
Name
VeraDermics
Legal name
VeraDermics, Inc.
Website
https://veradermics.com
Company type
Public
Founded year
2019
Operating status
Ipo
Headcount range
51–100 employees
Short description
VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043.
Ownership category
akta.pro rank

VeraDermics industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYCRABABAE
Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth)

Keywords

  • Dermatology therapeutics
  • Pattern hair loss
  • Oral minoxidil
  • Extended-release drug delivery
  • Clinical-stage biopharmaceutical

Where VeraDermics is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices1 record

Markets served

VeraDermics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-revenue clinical stage: Veradermics is a late clinical-stage biopharmaceutical company with no product revenue. The company reported a net loss of $53.81 million for the twelve months ending September 30, 2025, with zero product revenue. Future revenue model will be based on pharmaceutical product sales of VDPHL01 upon FDA approval, with Jefferies modeling approximately $2 billion in peak adjusted U.S. sales.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

VeraDermics product offering

Product offering

Core offering

Veradermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for pattern hair loss (androgenetic alopecia) in men and women. The sustained-release formulation maintains therapeutic plasma concentrations for 15-24 hours versus 4-6 hours for immediate-release oral minoxidil, with a release profile designed to avoid cardiac activity threshold spikes. VDPHL01 is currently in three Phase 3 registration-directed clinical trials (Studies 302 and 304 in males, Study 306 in females) and is being positioned as the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.

Product overview

VeraDermics is a single-product-platform late clinical-stage biopharmaceutical company whose offerings are centered on VDPHL01, its lead investigational extended-release oral minoxidil candidate for pattern hair loss, evaluated through three Phase 3 trials (Study 302 in males, Study 304 in males, and Study 306 in females). VDPHL01 is the core asset around which all current clinical and commercial activity is organized, supported by a small portfolio of exploratory pipeline assets in alopecia areata, common warts, and molluscum contagiosum that may be advanced in the future. The company is dermatologist-founded and primarily delivers value through advancing VDPHL01 through FDA registration and commercialization rather than offering a multi-module SaaS-style platform.

Differentiator

Problem solved

Functional benefit

Products and services

  • VDPHL01 VDPHL01 is a proprietary, extended-release oral minoxidil tablet designed specifically for pattern hair loss in men and women. The extended-release formulation extends minoxidil plasma exposure to 15-24 hours versus 4-6 hours for immediate-release, while avoiding cardiac threshold spikes. Currently in three Phase 3 clinical trials (Studies 302 and 304 in males, Study 306 in females) with patent protection extending to 2043.
  • Alopecia Areata Program Exploratory pipeline asset in alopecia areata developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01, generated from the founders' real-world clinical experience as dermatologists.
  • Common Warts Program Exploratory pipeline asset in common warts treatment based on a dissolvable microneedle patch platform; part of Veradermics' broader dermatology portfolio originally developed as the company's lead program.
  • Molluscum Contagiosum Program Exploratory pipeline asset in molluscum contagiosum developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01.

Quantifiable outcome

  • 30.3 hairs/cm² (once-daily) and 33.0-37.7 hairs/cm² (twice-daily) increase in target area hair count at Month 6 vs. 7.3 hairs/cm² for placebo (p<.0001)
  • +5 more outcomes

Companies that use VeraDermics

Customer profile

Segments3 records

Ideal customer profiles3 records

VeraDermics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

VeraDermics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and major.

  • Achieve Life SciencesminorStrategic or Co-development Partner · 1 June 2026Veradermics CEO Reid Waldman, MD was appointed to Achieve Life Sciences' Board of Directors in June 2026, alongside Jeffrey Farrow. The appointment brings Veradermics' CEO expertise in aesthetics and dermatology therapeutics to Achieve's cytisinicline pipeline (smoking cessation NDA and vaping cessation Breakthrough Therapy-designated program).
  • J.W. Childs AssociatesmajorStrategic or Co-development PartnerJohn W. Childs, chairman of J.W. Childs Associates (private equity firm focusing on life sciences), serves on Veradermics' board of directors. J.W. Childs Associates is an early investor in the company. Mr. Childs also serves on boards of Biohaven Pharmaceuticals, Pyramid Biosciences, OMAX Health, Basin Holdings, and Realm LLC.
  • American Academy of DermatologymajorGTM or Marketing PartnerVeradermics presented VDPHL01 data at the AAD Annual Meeting in Denver (March 2026), reaching the dermatology clinical community. Board member Jane Grant-Kels, MD previously served on the Board of Directors of the American Academy of Dermatology.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

VeraDermics competitors and assessment

Company assessment

Direct peers

  • Dermavant Sciences: Dermatology-focused biopharma with VTAMA (tapinarof) for psoriasis and atopic dermatitis, now part of Organon. Specialty dermatology pipeline and commercial model align directly with Veradermics' planned physician-channel and field-force GTM.
  • Sun Pharmaceutical Industries: India-based global generic and specialty pharma that markets Loniten (immediate-release oral minoxidil), the off-label incumbent for pattern hair loss. Direct competitor to VDPHL01 given overlapping active ingredient and prescriber base.
  • Revance Therapeutics: Aesthetic dermatology biopharma behind DAXXIFY and the former RHA filler line (sold to Crown Laboratories). Closely comparable aesthetics-focused specialty pharma model with dermatologist field sales force and similar cash-pay consumer dynamics to Veradermics' planned VDPHL01 launch.
  • Arcutis Biotherapeutics: Dermatology-focused biopharmaceutical company with approved topical treatments (ZORYVE) for plaque psoriasis and atopic dermatitis, plus pipeline in alopecia areata. Comparable late clinical-to-commercial dermatology specialty model with similar prescriber base and GTM motion.
  • Aclaris Therapeutics: Clinical-stage dermatology biopharma developing JAK inhibitors for alopecia areata and other inflammatory skin conditions. Most directly comparable to Veradermics in late-stage dermatology pipeline focus, public-company scale, and single-asset commercial economics.

Broad incumbents

  • Galderma Holding AG: Global dermatology specialty company spanning aesthetics, prescription dermatology, and consumer skincare. Comparable prescriber base and aesthetic dermatology channel that Veradermics will rely on for VDPHL01 commercialization.
  • Eli Lilly and Company: Global biopharma that signaled a stake of up to 4.9% in Veradermics at IPO. Comparable as a potential strategic acquirer with significant aesthetics/dermatology franchise interest and financial capacity to acquire Veradermics outright post-NDA.
  • AbbVie (Allergan Aesthetics): Global biopharma whose Allergan Aesthetics unit (Botox, CoolSculpting, Latisse) dominates aesthetic medicine. Comparable cash-pay aesthetics channel, dermatologist relationships, and potential acquirer profile for Veradermics.
  • Pfizer Inc. Global biopharma that markets Rogaine (topical minoxidil), the incumbent OTC/prescription brand in pattern hair loss. Represents the established competitive incumbent VDPHL01 must displace, with massive DTC marketing scale.
  • Organon & Co. Global women's health and dermatology specialty company with a portfolio including VTAMA and established dermatology sales infrastructure. Relevant given VDPHL01's female PHL opportunity and potential strategic acquirer profile for Veradermics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VeraDermics social profiles

Digital presence

VeraDermics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VeraDermics leadership team

Management profile

Number of profiles

Profiles10 records

VeraDermics funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VeraDermics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VeraDermics

What does VeraDermics do?

Veradermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for pattern hair loss (androgenetic alopecia) in men and women. The sustained-release formulation maintains therapeutic plasma concentrations for 15-24 hours versus 4-6 hours for immediate-release oral minoxidil, with a release profile designed to avoid cardiac activity threshold spikes. VDPHL01 is currently in three Phase 3 registration-directed clinical trials (Studies 302 and 304 in males, Study 306 in females) and is being positioned as the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.

Is VeraDermics a public or private company?

VeraDermics is a public company. It is classified as public and is currently ipo.

When was VeraDermics founded?

VeraDermics was founded in 2019. It employs 51 to 100 people.

Where is VeraDermics based?

VeraDermics is headquartered in New Haven, United States, in the North America region.

How does VeraDermics make money?

One revenue line is on record: pre-revenue clinical stage.

Who are VeraDermics's main competitors?

Direct peers on record are Dermavant Sciences, Sun Pharmaceutical Industries, Revance Therapeutics, Arcutis Biotherapeutics and Aclaris Therapeutics. Broad incumbents are Galderma Holding AG, Eli Lilly and Company, AbbVie (Allergan Aesthetics), Pfizer Inc. and Organon & Co..

Does VeraDermics have an API?

No public API is recorded for VeraDermics.

What industry is VeraDermics in?

VeraDermics's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingVeradermics to Present at Jefferies Global Healthcare ConferenceVeradermics management will present at the Jefferies Global Healthcare Conference in London on Nov. 19, 2026, at 8:30 a.m. GMT. The presentation is scheduled for 3:30 a.m. EST.Quiver QuantitativeVeradermics Slides as Investors Digest Recent Trial Updates and New Filing | MANE Stock NewsVeradermics stock fell 10.5% after the company released clinical updates and quarterly results, which included a net loss and a new filing disclosing planned insider stock sales. Insiders sold 15 times in the past six months, with no purchases, and hedge fund activity shows mixed institutional moves.The future of tradingVeradermics Presents VDPHL01 Data Showing Significant Hair Growth in Two Male Pattern Hair Loss StudiesVeradermics presented VDPHL01 data showing significant hair growth in two male pattern hair loss studies. Twice-daily dosing increased six-month target area hair counts by 36.4 versus 6.6 with placebo in Study 304, and 33.0 versus 7.3 in Study 302. Patient-reported improvement rates reached 68.7% in Study 304 versus 62.9% in Study 302.MarketScreenerVeradermics, Incorporated Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Veradermics reported a Q3 net loss of $21 million and a nine-month net loss of $71.73 million, both higher than the prior year. The company is developing VDPHL01, an oral minoxidil formulation for pattern hair loss, and is conducting a Phase II trial.Seeking AlphaVeradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss TranscriptVeradermics reported positive topline results from Part B of Study 302, a Phase II/III trial of VDPHL01 in males with mild-to-moderate pattern hair loss. The company's CEO and CFO discussed the findings on a conference call, with slides posted on the investor website.FiercePharmaVeradermics wraps phase 3 program in men with 'better-than-expected' hair growth at 1 yearVeradermics reported topline results from its phase 3 trial in men with pattern hair loss, showing VDPHL01 achieved continued hair growth through one year. The twice-daily dose group saw non-vellus hair count rise 43.9 hairs/cm² at 12 months, the highest in the program, with no serious adverse events. The company awaits female trial results in 2027.American Banking and Market NewsVeradermics, Incorporated $MANE Stock: Alps Advisors Inc. Boosts PositionAlps Advisors Inc. increased its stake in Veradermics by 31.2% in Q3, holding 55,356 shares worth $6.711 million. Analysts have a consensus "Moderate Buy" rating with a price target of $163.86, while insiders sold 961,000 shares in the last three months.Hartford Business JournalCT Innovations generates $51.4M in 1Q venture proceeds, nearing full-year recordConnecticut Innovations generated $51.4 million in venture proceeds during fiscal 2027's first quarter, nearly matching its fiscal 2026 record of $66.5 million. The proceeds, driven by Veradermics' IPO, represented about 77% of the prior year's total, while Q1 investments totaled $15.6 million.Naver비만 다음은 탈모?…일라이 릴리, 투자·인수 행보 주목[클릭 e종목]Eli Lilly is investing in hair-loss drug developers, including Veradermics, Absci, and Amplifica. The company has shown interest in Veradermics' oral minoxidil, which completed phase 3 trials. A researcher sees Lilly as likely to acquire a hair-loss drug developer in the medium-to-long term.PMLiVEVeradermics announces phase 3 results for oral minoxidil for hair lossVeradermics announced positive phase 3 results for its oral minoxidil VDPHL01 in 536 men, meeting all primary and secondary endpoints. The trial showed rapid hair growth with no serious adverse events. The company plans to report longer-term data from Study '302' later this year.